Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer

Steen Riisgaard de Blanck, Jonas Scherman Rydhög, Klaus Richter Larsen, Paul Frost Clementsen, Mirjana Josipovic, Marianne Camille Aznar, Per Munck af Rosenschöld, Rasmus Irming Jølck, Lena Specht, Thomas Lars Andresen, Gitte Fredberg Persson

Research output: Contribution to journalArticlepeer-review

Abstract

Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.

Original languageEnglish
Pages (from-to)24-28
JournalClinical and Translational Radiation Oncology
Volume13
DOIs
Publication statusPublished - 2018 Nov
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018 The Authors

Subject classification (UKÄ)

  • Radiology, Nuclear Medicine and Medical Imaging
  • Cancer and Oncology

Free keywords

  • EBUS
  • Endoscopic ultrasound
  • Image-guided radiotherapy
  • Liquid fiducial marker
  • NSCLC

Fingerprint

Dive into the research topics of 'Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this